Table 2.
The results of meta-analyses for the association between deregulated exomiRs and overall survival (OS), and disease/relapse/progression-free survival (DFS/RFS/PFS) in patients with GI cancers
| Study groups | Included exomiRs | Test of association | Test of heterogeneity | ||
|---|---|---|---|---|---|
| HR (95% CI) | P-value | I2% | P-value | ||
| OS | |||||
| All studies | 52 | 1.998 (1.705–2.341) | < 0.001 | 76.564 | < 0.001 |
| The type of exomiRs deregulation | |||||
| Up-regulation | 37 | 2.053 (1.720–2.449) | < 0.001 | 66.043 | < 0.001 |
| Down-regulation | 15 | 1.789 (1.251–2.559) | 0.001 | 87.290 | < 0.001 |
| Type of cancer | |||||
| Colorectal | 21 | 2.928 (2.417–3.547) | < 0.001 | 19.747 | 0.204 |
| Gastric | 7 | 1.353 (0.827–2.214) | 0.229 | 88.803 | < 0.001 |
| Hepatocellular | 16 | 1.582 (1.264–1.979) | < 0.001 | 76.367 | < 0.001 |
| Pancreatic | 6 | 2.514 (1.478–4.279) | 0.001 | 48.243 | 0.085 |
| locally advanced rectal | 2 | 0.958 (0.601–1.525) | 0.856 | 0.000 | 0.506 |
| Sample size | |||||
| ≥ 100 | 29 | 2.306 (1.789–2.973) | < 0.001 | 81.157 | < 0.001 |
| < 100 | 23 | 1.659 (1.359–2.025) | < 0.001 | 65.182 | < 0.001 |
| Sample type | |||||
| Plasma | 27 | 1.890 (1.497–2.386) | < 0.001 | 82.109 | < 0.001 |
| Serum | 25 | 2.125 (1.752–2.578) | < 0.001 | 51.047 | 0.002 |
| Survival analysis | |||||
| Direct | 44 | 2.114 (1.719–2.601) | < 0.001 | 79.360 | < 0.001 |
| Indirect | 8 | 1.559 (1.368–1.776) | < 0.001 | 1.170 | 0.420 |
| NOS score | |||||
| ≥ 7 | 25 | 2.165 (1.577–2.972) | < 0.001 | 78.093 | < 0.001 |
| < 7 | 27 | 1.850 (1.534–2.231) | < 0.001 | 74.863 | < 0.001 |
| Ethnicity | |||||
| Asian | 46 | 2.085 (1.746–2.489) | < 0.001 | 78.377 | < 0.001 |
| Caucasian | 6 | 1.327 (0.934–1.886) | 0.115 | 25.255 | 0.245 |
| DFS/RFS/PFS | |||||
| All studies | 29 | 1.920 (1.641–2.245) | < 0.001 | 55.871 | < 0.001 |
| Deregulation | |||||
| Up-regulation | 21 | 2.086 (1.725–2.522) | < 0.001 | 41.988 | 0.023 |
| Down-regulation | 8 | 1.607 (1.218–2.122) | 0.001 | 72.320 | 0.001 |
| Type of cancer | |||||
| Colorectal | 9 | 2.105 (1.736–2.554) | < 0.001 | 0.000 | 0.734 |
| Gastric | 4 | 1.408 (0.781–2.539) | 0.256 | 86.773 | < 0.001 |
| Hepatocellular | 10 | 1.923 (1.651–2.239) | < 0.001 | 0.000 | 0.740 |
| Pancreatic | 4 | 3.195 (2.019–5.056) | 0.000 | 0.000 | 0.839 |
| Locally advanced rectal | 2 | 1.034 (0.758–1.410) | 0.834 | 0.000 | 0.567 |
| Sample size | |||||
| ≥ 100 | 15 | 1.911 (1.520–2.402) | < 0.001 | 64.800 | < 0.001 |
| < 100 | 14 | 1.890 (1.506–2.373) | < 0.001 | 45.085 | 0.034 |
| Sample type | |||||
| Plasma | 13 | 1.819 (1.317–2.510) | < 0.001 | 74.592 | < 0.001 |
| Serum | 16 | 1.906 (1.680–2.163) | < 0.001 | 0.000 | 0.633 |
| Survival analysis | |||||
| Direct | 20 | 2.019 (1.594–2.558) | < 0.001 | 67.219 | < 0.001 |
| Indirect | 9 | 1.809 (1.552–2.109) | < 0.001 | 0.000 | 0.725 |
| NOS score | |||||
| ≥ 7 | 14 | 1.803 (1.498–2.170) | < 0.001 | 41.843 | 0.050 |
| < 7 | 15 | 2.062 (1.571–2.706) | < 0.001 | 65.905 | < 0.001 |
| Ethnicity | |||||
| Asian | 26 | 1.998 (1.705–2.341) | < 0.001 | 50.425 | 0.002 |
| Caucasian | 3 | 1.109 (0.800–1.538) | 0.535 | 10.141 | 0.329 |